Información de la revista
Vol. 25. Núm. 1.
Páginas 1-2 (enero 2007)
Vol. 25. Núm. 1.
Páginas 1-2 (enero 2007)
Editorial
Acceso a texto completo
Modern Highly Active Antiretroviral Therapy-A Very Well Tuned Compass for a Rapidly Evolving Field
Visitas
3796
Julio S.G. Montaner
Autor para correspondencia
jmontaner@cfenet.ubc.ca
Correspondence: Dr. J.S.G. Montaner. BC Centre for Excellence in HIV/AIDS St. Paul's Hospital/University of British Columbia Room 667. 1081 Burrard Street Vancouver. British Columbia V6Z 1Y6. Canada.
Correspondence: Dr. J.S.G. Montaner. BC Centre for Excellence in HIV/AIDS St. Paul's Hospital/University of British Columbia Room 667. 1081 Burrard Street Vancouver. British Columbia V6Z 1Y6. Canada.
Professor of Medicine, University of British Columbia. Director, AIDS Research Program; St Paul's Hospital, Providence Health Care. Director, British Columbia Centre for Excellence on HIV/AIDS. Co-Director, Canadian HIV Trials Network. President Elect, International AIDS Society. Canada
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.C.J. Carpenter, M.A. Fischl, S.M. Hammer, M.S. Hirsch, D.M. Jacobsen, D.A. Katzenstein, et al.
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel.
JAMA, 276 (1996), pp. 146-154
[2.]
S.M. Hammer, M.S. Saag, M. Schechter, J.S. Montaner, R.T. Schooley, D.M. Jacobsen, et al.
International AIDS Society-USA Panel. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA Panel.
JAMA, 296 (2006), pp. 827-843
[3.]
Panel de Expertos de GESIDA y Plan Nacional sobre el SIDA.
Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de inmunodeficiencia humana (actualización enero de 2007).
Enferm Infecc Microbiol Clin, 25 (2007), pp. 32-53
[4.]
J.M. Gatell, D. Salmon-Ceron, A. Lazzarin, Van Wijnet al.
Efficacy and safety of atazanavir (ATV) based HAART in patients switched from a stable boosted/ unboosted protease-inhibitor (PI) treatment: the SWAN study.
10th European AIDS Conference, pp. 17-20
[5.]
J.S.G. Montaner, R. Hogg, E. Wood, T. Kerr, M. Tyndall, A.R. Levy, et al.
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.
Lancet, 368 (2006), pp. 531-536
[6.]
R.P. Walensky, A.D. Paltiel, E. Losina, L.M. Mercincavage, B.R. Schackman, P.E. Sax, et al.
The survival benefits of AIDS treatment in the United States.
J Infect Dis, 194 (2006), pp. 11-19
[7.]
S.H. Vermund.
Millions of life-years saved with potent antiretroviral drugs in the United States: A celebration, with challenges.
J Infect Dis, 194 (2006), pp. 1-5
Copyright © 2007. Elsevier España S.L.. Todos los derechos reservados